CYCLOSPORINE NEPHROTOXICITY IN CARDIAC ALLOGRAFT PATIENTS

Publisher Website
Google Scholar
Abstract
Renal function was observed retrospectively in a population of 228 adults who underwent a cardiac allograft at the University of Pittsburgh from June 1980 through June 1987, survived a minimum of one year, and received cyclosporine. Renal function was determined by serial measurement of serum creatinine concentration. Serum creatinine rose from 1.2.+-.0.0 mg/dl at time of hospital discharge to 2.0.+-.0.0 mg/dl at two and four years and 3.3.+-.0.1 mg/dl at seven years. The fall in renal function was biphasic, with a rapid decline (reciprocal creatinine slope -0.018 dl/mg-mo) through 24 months and a slower decline thereafter -0.0036 dl/mg/month. This occurred despite a progressive decrease in cyclosporine levels from 668.+-.23 ng/ml (whole blood RIA) to 380.+-.12 ng/ml at seven years. Three of 222 patients (1.6%) developed end-stage renal disease within 18 months of initiation of cyclosporine therapy. Only one additional patients of 26 followed through 54 months (3.8%) developed end-stage disease thereafter. The decline in renal function seen with cyclosporine is rapid in the first 18 months, with a slower but continuing decline seen with later follow up. At least in heart transplantation, the risk of end-stage renal disease is significant but not prohibitive.